Aegerion Pharma (AEGR) Posts Smaller-than-Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:15 PM ESTCAMBRIDGE, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business update for the fourth quarter and full year of 2015.
Overview
Aegerion recorded total net product sales of $49.0 million in the fourth quarter of 2015. Aegerion recorded total net product sales of $239.9 million for the full year... More